Vincerx Pharma and Oqory reveal merger and cancer drug data
SAN MATEO, Calif. - Vincerx Pharma, Inc. (NASDAQ:VINC), a clinical-stage biopharmaceutical company with a current market capitalization of $2.77 million, and Oqory, Inc. announced promising results ...
Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans
The company has already cut its workforce, seen a leadership change and agreed to be acquired. Here's what's next.
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258
OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...
Vincerx Pharma, Inc. Announces Reverse Stock Split
Vincerx’s Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025SAN MATEO, Calif., Jan. 23, 2025 (GLOBE ...
Vincerx Pharma enters at-the-market equity offering deal
Vincerx Pharma, Inc. (NASDAQ:VINC), a pharmaceutical company, announced today an agreement with H.C. Wainwright & Co., LLC to sell up to $30 million of its common stock in an at-the-market equity ...
ETF Daily News5d
Vincerx Pharma (NASDAQ:VINC) Implements 1-for-20 Reverse Stock Split
Vincerx Pharma, Inc., a biopharmaceutical company focused on developing innovative therapeutics for cancer patients, announced a significant corporate action regarding its common stock.
Vincerx Pharma board aproves 1-for-20 reverse stock split
Vincerx Pharma (VINC) announced that its board of directors approved a 1-for-20 reverse stock split of its issued shares of common stock, which ...
Morningstar7d
Vincerx Pharma, Inc. Announces Reverse Stock Split
SAN MATEO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through ...